FDA Approves Lumisight and Lumicell DVS for Residual Breast

The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.

Related Keywords

Howard Hechler , Imaging Drugs Advisory Committee , Lumicell Inc , Lumicell Direct Visualization System , Fluorescence Guidance , Breast Cancer Lumpectomy ,